
UP-TO-DATE, RESEARCH BASED INFORMATION ABOUT PSYCHEDELICS.
IUPHAR-review: The integration of classic psychedelics into current substance use disorder treatment models
We suggest that classic psychedelic-assisted therapies can be integrated into most mainstream evidence-based SUD treatments that are currently used in clinical settings, indicating broad compatibility of classic psychedelics with contemporary SUD treatment paradigms.
Greater subjective effects of a low dose of LSD in participants with depressed mood
These findings suggest that an acute low dose of LSD (26 µg) elicits more pronounced positive mood and stimulant-like effects, as well as stronger altered states of consciousness in individuals with depressive symptoms, compared to non-depressed individuals.
Single-dose synthetic psilocybin with psychotherapy for treatment-resistant bipolar type II major depressive episodes: A nonrandomized controlled trial
The findings in this open-label nonrandomized controlled trial suggest efficacy and safety of psilocybin with psychotherapy in BDII depression and supports further study of psychedelics in this population.
Tim Ferriss podcast with Dr Willoughby Britton — The hidden risks of meditation, overlaps with psychedelic risks, harm reduction strategies, how to choose a retreat, near-death experiences, and more
Tim Ferriss talks with Dr Willoughby Britton about her ground-breaking (and often unpopular) research highlighting potential dangers and worrying frequency of adverse effects associated with meditation practices (and similarly psychedelics).
The risk of chronic psychedelic and MDMA microdosing for valvular heart disease
We conclude that VHD is a potential risk with chronic psychedelic microdosing, but further studies are necessary to better define this risk.
The virtual trip
The Virtual Trip is filling your table full of psychedelic sessions for your holiday week. Grab your laptop or phone, a warm drink, and your stretchy pants, and get ready to enjoy our largest video release yet
“I'm not allowed to touch the mushrooms”: 5 Questions for Oregon-based facilitator Josh Goldstein
Goldstein helps train other facilitators and guides psilocybin sessions with clients in Bend, Oregon ... We spoke with Goldstein about his role as a licensed facilitator, and how it differs from his work in the underground.
When the trial ends: The case for post-trial provisions in clinical psychedelic research
We show how conceiving of post-trial provision as an integral site of the research process, and an appropriate destination for research funding, will serve to develop the infrastructure necessary for the post-legalisation psychedelic medicine ecosystem.
Psychedelic-assisted psychotherapy: Where is the psychotherapy research?
PAP is a highly unique and transdisciplinary intervention, and future research designs should consider transdisciplinary research methodologies to identify best practices and inform federal guidelines for PAP administration.
Psychiatric risks for worsened mental health after psychedelic use
We infer that the presence of a personality disorder may represent an elevated risk for psychedelic use, and hypothesize that the importance of psychological support and good therapeutic alliance may be increased in this population.
Trait mindfulness and personality characteristics in a microdosing ADHD sample: a naturalistic prospective survey study
Trait mindfulness, specifically description and non-judging of inner experience, was increased, and neuroticism was decreased after 4 weeks of MD compared to baseline. The remaining personality traits remained unchanged. Using conventional medication and/or having comorbid diagnoses did not change the MD-induced effects on mindfulness and personality traits after 4 weeks. Conclusion: MD induced changes in otherwise stable traits. Future placebo-controlled studies are warranted to confirm whether these changes occur in a controlled setting.